News: H Lundbeck A/S (HLUKF.PK)

HLUKF.PK on OTC Markets Group

20.27USD
26 Jan 2015
Change (% chg)

-- (--)
Prev Close
$20.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
848
52-wk High
$31.33
52-wk Low
$19.09

Search Stocks
Select another date:

Mon, Dec 22 2014

BRIEF-Lundbeck to research link between immune system and brain diseases

* Is involved in a public-private partnership that may lead way to improved treatment of brain diseases

BRIEF-Lundbeck discontinues development of desmoteplase and narrows 2014 profit guidance

* Said on Wednesday the company would discontinue further development of desmoteplase

BRIEF-Lundbeck: FDA accepts for review supplemental New Drug Application of Abilify Maintena

* U.S. FDA accepts for review supplemental New Drug Application (sNDA) for a proposed new injection site - the deltoid muscle of the arm - for Abilify Maintena for extended-release injectable suspension Source text: http://bit.ly/1GoCd11 Further company coverage: (Gdynia Newsroom)

BRIEF-Lundbeck presents New Phase III studies of Brexpiprazole

* Says brexpiprazole demonstrates statistically significant effects in New Phase III studies in adult patients with schizophrenia

BRIEF-Lundbeck presents results of Brintellix studies

* Study reveals Brintellix (vortioxetine) affects underlying brain systems involved in working memory in people remitted from depression

BRIEF-H Lundbeck A/S: US FDA approves the labeling update of Abilify Maintena (aripiprazole)

* Said on Sunday US FDA approved the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension to describe new clinical data for the treatment of acutely relapsed adults with schizophrenia

UPDATE 1-Lundbeck's CEO resigns after breach of company rules

COPENHAGEN, Nov 24 - Danish pharmaceutical company Lundbeck's chief executive Ulf Wiinberg has resigned because of a breach in the company's code of conduct relating to shares he received in a biotech group.

Lundbeck's CEO resigns after breach of company rules

COPENHAGEN, Nov 24 - Ulf Wiinberg has resigned as chief executive of Danish pharmaceutical company Lundbeck because of a breach in company's code of conduct.

BRIEF-Ulf Wiinberg resigns as CEO of Lundbeck

* Resignation is a consequence of Ulf Wiinberg breaching company's Code of Conduct

BRIEF-Lundbeck Q3 EBIT DKK 94 million beats expectations

* Solid growth of new products, positive pipeline development and financial outlook maintained

Select another date:
Search Stocks